Osteosarcoma Conventional treatment vs. gene therapy

被引：91

作者：

Tan, Mei Lin ^{[1
,2
]}

Choong, Peter F. M. ^{[1
,2
,3
]}

Dass, Crispin R. ^{[1
,2
]}

机构：

[1] Univ Melbourne, St Vincents Hosp Melbourne, Dept Orthopaed, Fitzroy, Vic 3065, Australia

[2] Univ Melbourne, St Vincents Hosp Melbourne, Dept Surg, Fitzroy, Vic 3065, Australia

[3] Peter MacCallum Canc Inst, Bone & Soft Tissue Sarcoma Serv, Melbourne, Vic 3000, Australia

来源：

CANCER BIOLOGY & THERAPY | 2009年 / 8卷 / 02期

关键词：

osteosarcoma; treatment; gene therapy; surgery; chemotherapy; radiotherapy; EPITHELIUM-DERIVED FACTOR; CHITOSAN-DNA NANOPARTICLES; HIGH-GRADE OSTEOSARCOMA; HIGH-DOSE METHOTREXATE; SMALL INTERFERING RNA; IN-VIVO; ANTHRACYCLINE CARDIOTOXICITY; OLIGONUCLEOTIDE DELIVERY; COMBINATION CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY;

D O I：

10.4161/cbt.8.2.7385

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Osteosarcoma (OS) remains the most common primary malignant bone cancer affecting children and adolescents. Majority of patients are subjected to surgery and chemotherapy with limited alternatives to consider. However, with increasing knowledge of the molecular pathogenesis of OS, advancements in OS therapy research fields have developed potential agents for a more targeted and localised approach to treatment. Thus, this review attempts to examine some common treatment strategies (surgery, radiotherapy and chemotherapy) employed clinically as well as recent developments in newer experimental therapy methods (gene therapy) which might potentially benefit patients.

引用

页码：106 / 117

页数：12

共 156 条

[61] LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 [J].

Hacein-Bey-Abina, S ;

Von Kalle, C ;

Schmidt, M ;

McCcormack, MP ;

Wulffraat, N ;

Leboulch, P ;

Lim, A ;

Osborne, CS ;

Pawliuk, R ;

Morillon, E ;

Sorensen, R ;

Forster, A ;

Fraser, P ;

Cohen, JI ;

de Saint Basile, G ;

Alexander, I ;

Wintergerst, U ;

Frebourg, T ;

Aurias, A ;

Stoppa-Lyonnet, D ;

Romana, S ;

Radford-Weiss, I ;

Gross, F ;

Valensi, F ;

Delabesse, E ;

Macintyre, E ;

Sigaux, F ;

Soulier, J ;

Leiva, LE ;

Wissler, M ;

Prinz, C ;

Rabbitts, TH ;

Le Deist, F ;

Fischer, A ;

Cavazzana-Calvo, M .

SCIENCE, 2003, 302 (5644) :415-419

[62] Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications [J].

Hartman, Zachary C. ;

Appledorn, Daniel M. ;

Amalfitano, Andrea .

VIRUS RESEARCH, 2008, 132 (1-2) :1-14

[63] Osteosarcoma cell lines display variable individual reactions on wildtype P53 and Rb tumour-suppressor transgenes [J].

Hellwinkel, OJC ;

Müller, J ;

Pollmann, A ;

Kabisch, H .

JOURNAL OF GENE MEDICINE, 2005, 7 (04) :407-419

[64] Liposomal encapsulated anti-cancer drugs [J].

Hofheinz, RD ;

Gnad-Vogt, SU ;

Beyer, U ;

Hochhaus, A .

ANTI-CANCER DRUGS, 2005, 16 (07) :691-707

[65]

HRYNIUK WM, 1987, SEMIN ONCOL, V14, P3

[66] Chitosan nanoparticles as delivery systems for doxorubicin [J].

Janes, KA ;

Fresneau, MP ;

Marazuela, A ;

Fabra, A ;

Alonso, MJ .

JOURNAL OF CONTROLLED RELEASE, 2001, 73 (2-3) :255-267

[67] Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients [J].

Jensen, BV ;

Skovsgaard, T ;

Nielsen, SL .

ANNALS OF ONCOLOGY, 2002, 13 (05) :699-709

[68] Clinical research: Death prompts a review of gene therapy vector [J].

Kaiser, Jocelyn .

SCIENCE, 2007, 317 (5838) :580-580

[69]

KAMEN BA, 2003, CANC MED, V6

[70]

KANSARA M, 2007, MOL PATHOGENESIS OST, V26, P1

← 2 3 4 5 6 7 8 9 10 11 →